Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00051142 | A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) | PHASE3 | COMPLETED | - | — | — | Feb 1, 2001 | Jun 1, 2004 | Aug 5, 2008 | 1 | United States |
| NCT00051155 | A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT) | PHASE3 | COMPLETED | - | — | — | Jan 1, 2001 | Jul 1, 2004 | Aug 5, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | - |
| Latanoprost | DRUG | - |
| Travoprost (0.004%) | DRUG | - |
| Latanoprost (0.005%)/Timolol (0.5%) | DRUG | - |
Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.